Puma Biotechnology Earnings Call Transcripts
Fiscal Year 2026
-
Q3 revenue was $55.1M and adjusted net income was $8.0M; NERLYNX U.S. demand rose 5% YoY. FY26 net income guidance increased to $20M-$22M, while alisertib studies advanced and China royalties faced a lower rate.
-
NERLYNX continues to drive revenue growth, with raised guidance for 2026 and strong U.S. and international sales. Alisertib's phase II trials in breast and lung cancer show promising efficacy, especially in biomarker-defined subgroups, with expanded enrollment and further data expected in late 2026.
-
Q2 2026 saw strong revenue and net income growth, driven by increased NERLYNX demand and disciplined expense management. Guidance for FY 2026 was raised for both product revenue and net income, while the company remains debt-free and continues to advance its clinical pipeline.
-
Q1 2026 saw NERLYNX revenue decline sequentially due to inventory drawdown, but new patient starts rose 25% and the company is now debt-free. Updated guidance raises FY 2026 revenue and net income expectations, with strong clinical progress in biomarker-driven trials.
-
NERLYNX continues to show strong commercial growth, with increasing revenues and improved patient tolerability. Alisertib advances in phase II trials for breast and lung cancers, with interim and full data readouts expected in 2026. Financial stability is supported by profitability and a near debt-free position.
Fiscal Year 2025
-
Q4 2025 saw strong revenue growth, with NERLYNX net product revenue and royalties both rising significantly. Clinical trials for alisertib are ahead of schedule, and full-year profitability was achieved for the third consecutive year.
-
Q3 2025 saw net product revenue rise sequentially to $51.9M, with U.S. Nerlynx sales up and demand growth in key channels. Net income improved, and full-year guidance was raised for both revenue and profit, while R&D spending is set to increase due to faster trial enrollment.
-
NERLYNX continues to drive revenue growth, supported by improved dosing strategies and global partnerships. Alisertib advances in phase 2 trials for breast and lung cancers, with strong biomarker-driven potential and rapid enrollment. Interim data from key studies are expected by late 2025.
-
Q2 2025 saw strong revenue and net income growth, driven by increased NERLYNX sales and higher demand, especially in the specialty distributor channel. Clinical trials for alisertib are progressing ahead of schedule, and full-year guidance was raised for both revenue and net income.
-
Q1 2025 revenue was $46M, with NERLYNX net product revenue at $43.1M and net income at $3M GAAP. Guidance for FY 2025 includes $192M-$198M in net product revenue and $23M-$28M net income. Clinical programs and commercial strategies are advancing, with ongoing expense control.
-
NERLYNX continues to generate stable revenue with improved tolerability and strong U.S. and international market presence, while alisertib advances in phase II trials targeting biomarker-defined cancer subgroups. Multiple interim data readouts are expected in 2025.
Fiscal Year 2024
-
Q4 2024 revenue reached $59.1M, with NERLYNX net product revenue at $54.4M and net income at $19.3M. FY 2025 guidance projects flat product revenue, lower royalties due to China, and net income of $23–28M. Inventory build and regulatory approvals in new markets impacted results.
-
Q3 2024 saw strong revenue and net income growth, driven by higher NERLYNX sales and royalties, especially from China. Early alisertib trial data show improved tolerability and potential efficacy in biomarker-positive lung cancer. FY 2024 guidance remains positive.
-
Q2 2024 net product revenue rose to $44.4M, up from Q1 but down year-over-year, with a GAAP net loss of $4.5M. FY 2024 guidance projects $183M-$190M in net product revenue and $12M-$15M in net income. Ongoing clinical trials and new international approvals support future growth.